国产品牌,进口替代,不担心高关税

产品中心 抗体 配对抗体

所有图片(1/1)

sFlt-1 Recombinant Rabbit mAb (SDT-233-26)

货号: S0B3140

Datasheet COA
  • 价格: ¥3,850
  • 规格:
  • 数量:
斯达特大包装询价 大包装询价

产品介绍 引用文献(0) 评论(0)

产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    sFlt-1
  • 分子别名

    Soluble Fms-Like Tyrosine Kinase-1, sVEGFR-1
  • 免疫原

    Recombinant Protein
  • Accession

    P17948
  • 克隆号

    SDT-233-26
  • 抗体类型

    Recombinant mAb
  • 应用

    Sandwich ELISA, CLIA
  • 反应种属 ?

    Hu
  • 交叉反应

    Does not recognize PlGF
  • 纯化方式

    Protein A
  • 浓度

    2 mg/ml
  • 纯度

    >95% by HPLC
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS pH7.4, 0.03% Proclin 300
  • 储存条件

    12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

稀释度
应用 稀释度
Sandwich ELISA N/A
背景介绍
  • Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), reducing blood vessel growth through reduction of free VEGF and PlGF concentrations. In humans, sFlt-1 is important in the regulation of blood vessel formation in diverse tissues, including the kidneys, cornea, and uterus. Abnormally high levels of sFlt-1 have been implicated in the pathogenesis of preeclampsia. Preeclampsia (PE) is a hypertensive pregnancy disorder that occurs in approximately 2% to 4% of all pregnancies and is accompanied by substantial morbidity and mortality for both mother and infant and long-term risks for chronic diseases. The exact causes of PE are still unclear, but contributors are systemic endothelial dysfunction, impaired angiogenesis, and decreased vascular compliance. In recent years, research has focused primarily on soluble anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and pro-angiogenic factors, such as placental growth factor (PlGF). An anti-angiogenic imbalance upon increased sFlt-1 levels has been shown to be a critical factor in the pathogenesis of placentally associated disorders such as PE and is strongly associated with the crucial process of remodelling of the maternal spiral arteries. As an anti-angiogenic factor on the surface of vascular endothelial cells, sFlt-1 blocks the responses of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and PlGF. Those changes in the concentration of angiogenic factors can be measured in maternal blood samples–an elevated sFlt-1/PlGF ratio can occur weeks before clinical symptoms of PE arise. Therefore, measurement of the sFlt-1/PlGF ratio has become an established marker in clinical practice for early prediction of PE.

  • 验证数据

    • item.picture[0].fileOrgName

    引用文献(0)

    评论(0)

      共 0 条
      • 1
      共计0页,前往

      计算器

      email

      留言咨询